Hormonal contraception and ovarian pathology

European Journal of Contraception and Reproductive Health Care

Volumn 2, Issue 4, 1997, Pages 207-211

  Crosignani, P G ^a   Vegetti, W ^a   Bianchedi, D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Hormonal contraception; Ovarian function; Ovarian pathology

Indexed keywords

ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT;

DRUG EFFECT; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMAN; HYPERANDROGENISM; OVARY; OVARY DISEASE; OVULATION; PHYSIOLOGY; REVIEW; UTERUS BLEEDING;

CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; HYPERANDROGENISM; OVARIAN DISEASES; OVARY; OVULATION; RECEPTORS, ESTROGEN; UTERINE HEMORRHAGE;

EID: 0031306126     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189709165296     Document Type: Article

References (18)

1. Kuhl H, Gahn G, Romberg G, et al. Randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception 1985; 31: 583-93
2. Killick S, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13
3. Crosignani PG,Testa G,Vegetti W, et al. Ovarian activity during regular oral contraceptive use. Contraception 1996; 54: 271-3
4. Givens JR, Andersen RN, Wiser WL, et al. The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone binding capacity in hirsute women. Am J Obstet Gynecol 1976; 124: 333-9
5. Maroulis GB. Evaluation of hirsutism and hyperandrogenemia. Fertil Steril 1981: 36: 273-305
6. Bonne C, Saurat JH, Chivot M, et al. Androgen receptor in human skin. Br J Dermatol 1977; 97: 501-3
7. Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993: 60: 75-9
8. Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception 1988; 38: 419-28
9. Vegetti W, Testa G, Maggioni P, et al. An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism. Gynecol Obstet Invest 1996; 41: 260-8
10. Vercellini P, Fedele L, Bianchi S, et al. Pelvic denervation for chronic pain associated with endometriosis: fact or fancy? Am J Obstet Gynecol 1991: 165: 745-9
11. Metzger DA, Luciano AA. Hormonal therapy of endometriosis. Obstet Gynecol Clin North Am 1989; 16: 105-22
12. Noble AD, Letchworth AT.Treatment of endometriosis: a study of medical management. Br J Obstet Gynaecol 1980; 87: 726-8
13. Moghissi K.Treatment of endometriosis with estrogen progestin combination and progestogen alone. Clin Obstet Gynecol 1988; 31: 823-8
14. Lewis MA, Heinemann LAJ, Spitzer WO, et al.The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception 1997; 56; 129-40
15. Crosignani PG, La Vecchia C. In Dooley MM, Brincat MO, eds. Understanding Common Disorders in Reproductive Endocrinology. Chichester: Wiley J. & Sons Ltd, 1994: 123-43
16. Westhoff C. Ovarian cancer. Annu Rev Public Health 1996; 17; 85-96
17. Kay TJA, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988; 57: 205-12
18. Washington AE, Gove S, Schachter J. Oral contraceptives, Chlamydia trachomatis infection and pelvic inflammatory disease. J Am Med Assoc 1985; 253: 2246-52